This study is completed in the United States. It is testing TNX-102 SL for PTSD.
PTSDDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether TNX-102 SL Tablets may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive TNX-102 SL Tablets, attend study visits with the research team. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: April 14, 2015
Recruitment status
Completed
Enrollment listed in the registry
159
Sponsor
Tonix Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02421679
Official title
A 12-Week, Open-Label, Multicenter, Extension Study To TNX-CY-P201 To Evaluate The Safety And Efficacy Of TNX-102 SL Taken Daily At Bedtime In Patients With Military-Related PTSD And Related Conditions
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT02421679. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 22 sites
Tuscaloosa VA Medical Center
Tuscaloosa, Alabama
Site status: Not listed — confirm with the team
Noesis Pharma
Phoenix, Arizona
Site status: Not listed — confirm with the team
Sun Valley Research Center
Imperial, California
Site status: Not listed — confirm with the team
Synergy Clinical Research
National City, California
Site status: Not listed — confirm with the team
Excell Research, Inc
Oceanside, California
Site status: Not listed — confirm with the team
Neuropsychiatric Research Center of Orange County
Orange, California
Site status: Not listed — confirm with the team
CITRIALS
Riverside, California
Site status: Not listed — confirm with the team
CESAMH
San Diego, California
Site status: Not listed — confirm with the team
Cns, Inc.
Torrance, California
Site status: Not listed — confirm with the team
Sarkis Clinical Trials
Lake City, Florida
Site status: Not listed — confirm with the team
Compass Research North, LLC
Leesburg, Florida
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Site status: Not listed — confirm with the team
Atlanta Center For Medical Research
Atlanta, Georgia
Site status: Not listed — confirm with the team
Great Lakes Clinical Trials
Chicago, Illinois
Site status: Not listed — confirm with the team
Novex Clinical Research
New Bedford, Massachusetts
Site status: Not listed — confirm with the team
Premier Psychiatric Research Institute, Inc.
Lincoln, Nebraska
Site status: Not listed — confirm with the team
Altea Research
Las Vegas, Nevada
Site status: Not listed — confirm with the team
Neurobehavioral Research, Inc.
Cedarhurst, New York
Site status: Not listed — confirm with the team
University of Cincinnati College of Medicine
Cincinnati, Ohio
Site status: Not listed — confirm with the team
University Hospitals Case Medical Center
Cleveland, Ohio
Site status: Not listed — confirm with the team
Clinical Trials of Texas
San Antonio, Texas
Site status: Not listed — confirm with the team
Northwest Clinical Research Center
Bellevue, Washington
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition. Patients recruited into this trial are those who have successfully completed. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving TNX-102 SL. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Tonix Pharmaceuticals, Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
